Recent Security Class Actions

19 Days left to seek lead plaintiff status.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s FDA operations and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the preclinical data submitted in support of FTX-6058 showed safety concerns regarding potential hematological malignancies; (ii) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (iii) accordingly, the Company had overstated FTX-6058’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Fulcrum Therapeutics Inc. Common Stock (NASDAQ: FULC) Claim Form